LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Strona główna・Stock List・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Closed

SectorHealthcare

20.4 1.69

Buy Sell

Overview

Share price change

24h

Current

Min

19.5

Max

20.55

Key metrics
By Trading Economics
Income	-5M -47M
Sales	-480K 695K
EPS	-0.81
Profit margin	-4,007.83
Employees	186
EBITDA	-3.9M -55M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+197.41% upside

Dividends
By Dow Jones
Next Earnings	6 sie 2025

Market Stats
By TradingEconomics
Market Cap	-7.3M 1.3B
Previous open	18.71
Previous close	20.4

News Sentiment

By Acuity

50%

173 / 382 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

18.91 / 20.63 Support & Resistance

Celldex Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 maj 2025, 22:52 UTC

Earnings

Major Market Movers

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 maj 2025, 20:37 UTC

Top News

Earnings

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 maj 2025, 00:00 UTC

Market Talk

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 maj 2025, 23:47 UTC

Market Talk

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 maj 2025, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 maj 2025, 23:38 UTC

Market Talk

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 maj 2025, 23:14 UTC

Top News

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 maj 2025, 22:46 UTC

Top News

Acquisitions, Mergers, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 maj 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 maj 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 maj 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 maj 2025, 21:58 UTC

Earnings

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 maj 2025, 21:24 UTC

Earnings

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 maj 2025, 20:56 UTC

Market Talk

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 maj 2025, 20:54 UTC

Market Talk

Earnings

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 maj 2025, 20:54 UTC

Earnings

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 maj 2025, 20:51 UTC

Earnings

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 maj 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15 maj 2025, 20:50 UTC

Acquisitions, Mergers, Takeovers

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 maj 2025, 20:50 UTC

Earnings

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 maj 2025, 20:47 UTC

Earnings

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 maj 2025, 20:47 UTC

Earnings

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 maj 2025, 20:47 UTC

Earnings

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 maj 2025, 20:47 UTC

Earnings

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 maj 2025, 20:37 UTC

Earnings

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 maj 2025, 20:37 UTC

Earnings

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 maj 2025, 20:37 UTC

Earnings

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 maj 2025, 20:37 UTC

Earnings

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 maj 2025, 20:26 UTC

Top News

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 maj 2025, 20:25 UTC

Earnings

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Peer Comparison

Price change

Celldex Therapeutics Inc Forecast

Price Target

By TipRanks

197.41% upside

12 Months Forecast

Average 59.78 USD 197.41%

High 80 USD

Low 36 USD

Based on 10 Wall Street analysts offering 12 month price targets forCelldex Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Celldex Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

18.91 / 20.63Support & Resistance

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

173 / 382 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.